Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Fractyl Health, Inc. ( (GUTS) ).
On June 18, 2025, Fractyl Health, Inc. announced the issuance of two new U.S. patents that enhance its intellectual property portfolio, which protects its duodenal resurfacing innovations. These patents, issued on May 20 and June 17, 2025, are directed towards ablating duodenal mucosa using various forms of energy, reinforcing Fractyl’s leadership in metabolic disease treatment. The announcement underscores Fractyl’s commitment to advancing gut-targeted therapies for obesity and type 2 diabetes, with its lead product candidate, Revita, being a first-in-class treatment designed to remodel the duodenal lining. The company is also preparing for key data readouts from its ongoing pivotal study of Revita, which may demonstrate its potential in maintaining weight loss and supporting durable metabolic outcomes.
The most recent analyst rating on (GUTS) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Fractyl Health, Inc. stock, see the GUTS Stock Forecast page.
Spark’s Take on GUTS Stock
According to Spark, TipRanks’ AI Analyst, GUTS is a Neutral.
Fractyl Health’s overall stock score reflects substantial financial challenges and a negative valuation, which are offset by strong technical momentum and promising clinical progress. Recent corporate events point to potential future growth opportunities, though the financial instability and limited cash reserves remain significant risks.
To see Spark’s full report on GUTS stock, click here.
More about Fractyl Health, Inc.
Fractyl Health, Inc. is a metabolic therapeutics company focused on pioneering new approaches to treating metabolic diseases, including obesity and type 2 diabetes. The company aims to transform treatment from chronic symptomatic management to durable disease-modifying therapies targeting the root causes of these diseases. Fractyl Health is based in Burlington, MA, and has developed a robust intellectual property portfolio with numerous patents and applications in the U.S. and abroad.
Average Trading Volume: 296,742
Technical Sentiment Signal: Buy
Current Market Cap: $102.4M
Find detailed analytics on GUTS stock on TipRanks’ Stock Analysis page.